Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).

Daniel V.T. Catenacci,Minori Rosales,Jon M. Wigginton,Hyun Cheol Chung,Harry H. Yoon,Lin Shen,Markus Moehler,Yoon-Koo Kang

Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).

2020

Daniel V.T. Catenacci
Minori Rosales
Jon M. Wigginton
Hyun Cheol Chung
Harry H. Yoon
Lin Shen
Markus Moehler
Yoon-Koo Kang

TPS468Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care palliative 1st-line therapy for advanced HER2+ GEJ/GC patients (pts). M, an Fc-engineered anti-HER...

Keywords:

Cancer
Internal medicine
first line therapy
Margetuximab
Gastroesophageal Junction
Oncology
Medicine
Chemotherapy
Pathology
Trastuzumab
Monoclonal antibody
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations